All articles by Rebecca Panks

Rebecca Panks

The ten most promising cancer drugs being trialled

To meet rising demand, companies worldwide are striving to develop cost-effective and innovative therapies for a wide variety of cancer types.

Novartis juvenile arthritis drug performs well in trial

Novartis’ ACZ885 (canakinumab) has demonstrated positive results in a Phase III trial involving patients with systemic juvenile idiopathic arthritis, a rare and serious childhood auto-inflammatory disease.

BARDA funds Vaxin to develop anthrax vaccine

Vaxin, a clinical-stage vaccine development company, has been awarded a $21.7m contract by the Office of Biomedical Advanced Research and Development Authority (BARDA) for the development of the company’s proprietary anthrax vaccine, AdVAV.